SPECIAL FEATURES

CCR Translations

2121  Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!  Harirahan Easwaran and Stephen B. Baylin  See article p. 2360

2124  Double Down for a Double Win  Pearl S. Huang  See article p. 2316

2127  Competing Risk Analyses: How Are They Different and Why Should You Care?  Rick Chappell  See article p. 2301

2130  Choosing Phase II Endpoints and Designs: Evaluating the Possibilities  Michael LeBlanc and Catherine Tangen  See article p. 2309

Molecular Pathways

2133  Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications  Robert J. Biggar

2138  Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus  Liying Yang, Fritz Francois, and Zhilei Pei

Review

2145  Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment  Asher A. Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, and Meletios A. Dimopoulos

HUMAN CANCER BIOLOGY

Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKTL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKTL  Naoko Kanemitsu, Yasushi Isebe, Azuchi Masuda, Shuji Momose, Morihiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, and Norio Komatsu


First Evidence That γ-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-κB Pathway

Kanjoormana A. Manu, Muthu K. Shanmugam, Lalitha Ramachandran, Feng Li, Chee Wui Fong, Alan Prem Kumar, Patrick Tan, and Gautam Sethi

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Eline Menu, Els Van Valkenborgh, Elke De Bryune, Anders Osterborg, Peter Atadja, Olle Larsson, Magnus Axelson, Ben Van Camp, Helena Jernberg-Wiklund, and Karin Vanderkerken

Improved Efficacy of Dendritic Cell-Based Immunotherapy by Cutaneous Laser Illumination

Xinyuan Chen, Qiuyan Zeng, and Mei X. Wu

Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas

Kan Zhai, Xiaobo Tian, Chen Wu, Ning Lu, Jiang Chang, Liming Huang, Tongwen Zhang, Yuling Zhou, Yan Qiao, Dianke Yu, Wen Tan, Jieping Chen, and Dongxin Lin

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

Xiaoyun Liao, Teppai Morikawa, Paul Lochhead, Yu Imamura, Aya Kuchiba, Mai Yamauchi, Katsuhiko Nosho, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Charles S. Fuchs, and Shuji Ogino

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

Kanwal P. Baghaw, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. Blumenschein Jr, and Ana M. Gonzalez-Angulo

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma


Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

Josep M. Llovet, Carol E.A. Peña, Chetan D. Lathia, Michael Shan, Gerold Meinhardt, and Jordi Bruix on behalf of the SHARP Investigators Study Group

The Use and Interpretation of Competing Risks Regression Models

James J. Dignam, Qiang Zhang, and Masha Kocherginsky

See commentary p. 2127

Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

Manish R. Sharma, Theodore G. Karrison, Yuyan Jin, Robert B. Ries, Michael L. Maitland, Walter M. Stadler, and Mark J. Ratain

See commentary p. 2130

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer


See commentary p. 2124

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

David S. Hong, Luis Vence, Gerald Falchook, Laszlo G. Radavanyi, Chengwen Liu, Vicki Goodman, Jeffery J. Legos, Sam Blackman, Antonio Scarmadillo, Razelle Kurzrock, Gregory Lizée, and Patrick Hwu

See commentary p. 2124
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, and Giuseppe Giaccone

Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study
Jonathan Shamash, Jimmy Jacob, Samir Agrawal, Thomas Powles, Katherine Mutsvangwa, Peter Wilson, and Justin Stebbing

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
Kim Walter, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez, Robert Soriano, Ling Hwu, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yau, and David S. Shames
See commentary p. 2121

Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, and Susan E. Bates

Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
David N. Finegold, Catherine J. Baty, Kelly Z. Knickelbein, Shelley Perschke, Sarah E. Noon, Diana Campbell, Jenny M. Karlsson, Diana Huang, Mark A. Kimak, Elizabeth C. Lawrence, Eleanor Feingold, Stephen D. Meriney, Adam M. Bruksy, and Robert E. Ferrell

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Elizabeth A. Punnoose, Siminder Atwal, Weiquan Liu, Rajiv Baja, Bernard M. Fine, Brett G.M. Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amer, Andrea Pirzkal, and Mark R. Lackner

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

CORRECTION
ABOUT THE COVER

RAF265 greatly reduces the activation of MEK1 in melanoma patient tumors. Photomicrograph showing immunohistochemical localization of a remaining low level of active phospho-MEK1 (green) in a melanoma patient tumor that was treated with RAF265 after being implanted into a nude mouse. Nuclei are stained with DAPI and appear blue. 20X magnification. For details, see the article by Su and colleagues on page 2184 of this issue.
Clinical Cancer Research

18 (8)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/8

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.